Table 1
Patient characteristics before high dose cyclophosphamide treatment
| Age/sex | Patient 1 41/female | Patient 2 56/male | Patient 3 41/female |
|---|---|---|---|
| MG, myasthenia gravis; iv, intravenous; Ig, immunoglobulin; qd, four times daily; bid, twice daily | |||
| Duration of MG (y) | 11 | 9 | 29 |
| MG severity class | IVb | IVb | IVb |
| AChr antibody | Undetectable | Undetectable | Detectable |
| Previous treatment | |||
| Pyridostigine | X | X | X |
| Thymectomy(ies) | 2 | 1 | 2 |
| iv Ig (no of infusions) | 1 | 1 | 62 |
| Prednisone | 10–100 mg qd, duration 3 years | 40–100 mg qd, duration 7 years | 10–60 mg qd, duration 4 years |
| Plasmapheresis (no. of procedures) | 217 | 14 | 16 |
| Azathioprine | 50 mg/d, duration 7 months limited by nausea/vomiting | 200 mg qd, duration 2 months limited by nausea/vomiting | 50–150 mg qd, duration 15 months |
| Oral cyclophosphamide | 100 mg qd, 28 months | ||
| Cyclosporine | 50–125 mg bid, duration 39 months | ||
| Cellcept | 250–500 mg qd, duration 7 months | ||
